New mRNA vaccine trial targets Hard-to-Treat lymphoma
NCT ID NCT07334574
First seen Jan 12, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This early-stage study tests a personalized mRNA vaccine (XP-006) in 20 adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. The main goal is to check safety and find the right dose, while also looking at how well the vaccine activates the immune system and controls the cancer. Participants must have already tried standard treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.